Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.224-227 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 227 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 224 |
| container_title | Blood |
| container_volume | 140 |
| creator | Allan, John N. Siddiqi, Tanya Kipps, Thomas J. Kuss, Bryone J. Badoux, Xavier C. Barrientos, Jacqueline C. Tedeschi, Alessandra Opat, Stephen Flinn, Ian W. Gonzalez Barca, Eva Jacobs, Ryan Szafer-Glusman, Edith Zhou, Cathy Szoke, Anita Wierda, William G. Ghia, Paolo Tam, Constantine S. |
| description | |
| doi_str_mv | 10.1182/blood-2022-160338 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_160338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122016354</els_id><sourcerecordid>S0006497122016354</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1858-307c6c815934cc438d801e271114257bb78aafc33a575960d4dd5884a22c63ff3</originalsourceid><addsrcrecordid>eNp9kctuUzEQhi0EEqHwAOxmmSwMvpyLA6sobSBSqkaQVmJ15GPPUY1O7Mr26eU5eSFcgsSO1Yw08_1z-Ql5z9kHzpX42I8hWCqYEJQ3TEr1gsx4LRRlTLCXZMYYa2i1bPlr8ialn4zxSop6Rn4dIup8RJ_hasomHDGBHjJGuPYWM5qs-xHh8ts5PLh8CxsXU6Y75xG2fZyy866HeUkXsB-nBDfoMQcz6keYl3zxqRCPaOF8ijq74OHfvPl-1Ab7sChQTIVdB1_0ptJd9E7jpjvIAWr4gTomuETrtIdNGMfwQEvNeci3COvV_rC9WR0u4Hue7NNb8mrQY8J3f-MZud5cHNZf6e7qy3a92lHDVa2oZK1pjOL1UlbGVFJZxTiKlnNeibrt-1ZpPRgpdd3Wy4bZytpaqUoLYRo5DPKM8JOuiSGliEN3F91Rx6eOs-7Zle6PK92zK93JlcJ8PjFYFrt3GLtkHHpTLovl2Z0N7j_0b5A3lbc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Allan, John N. ; Siddiqi, Tanya ; Kipps, Thomas J. ; Kuss, Bryone J. ; Badoux, Xavier C. ; Barrientos, Jacqueline C. ; Tedeschi, Alessandra ; Opat, Stephen ; Flinn, Ian W. ; Gonzalez Barca, Eva ; Jacobs, Ryan ; Szafer-Glusman, Edith ; Zhou, Cathy ; Szoke, Anita ; Wierda, William G. ; Ghia, Paolo ; Tam, Constantine S.</creator><creatorcontrib>Allan, John N. ; Siddiqi, Tanya ; Kipps, Thomas J. ; Kuss, Bryone J. ; Badoux, Xavier C. ; Barrientos, Jacqueline C. ; Tedeschi, Alessandra ; Opat, Stephen ; Flinn, Ian W. ; Gonzalez Barca, Eva ; Jacobs, Ryan ; Szafer-Glusman, Edith ; Zhou, Cathy ; Szoke, Anita ; Wierda, William G. ; Ghia, Paolo ; Tam, Constantine S.</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-160338</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.224-227</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1858-307c6c815934cc438d801e271114257bb78aafc33a575960d4dd5884a22c63ff3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Allan, John N.</creatorcontrib><creatorcontrib>Siddiqi, Tanya</creatorcontrib><creatorcontrib>Kipps, Thomas J.</creatorcontrib><creatorcontrib>Kuss, Bryone J.</creatorcontrib><creatorcontrib>Badoux, Xavier C.</creatorcontrib><creatorcontrib>Barrientos, Jacqueline C.</creatorcontrib><creatorcontrib>Tedeschi, Alessandra</creatorcontrib><creatorcontrib>Opat, Stephen</creatorcontrib><creatorcontrib>Flinn, Ian W.</creatorcontrib><creatorcontrib>Gonzalez Barca, Eva</creatorcontrib><creatorcontrib>Jacobs, Ryan</creatorcontrib><creatorcontrib>Szafer-Glusman, Edith</creatorcontrib><creatorcontrib>Zhou, Cathy</creatorcontrib><creatorcontrib>Szoke, Anita</creatorcontrib><creatorcontrib>Wierda, William G.</creatorcontrib><creatorcontrib>Ghia, Paolo</creatorcontrib><creatorcontrib>Tam, Constantine S.</creatorcontrib><title>Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kctuUzEQhi0EEqHwAOxmmSwMvpyLA6sobSBSqkaQVmJ15GPPUY1O7Mr26eU5eSFcgsSO1Yw08_1z-Ql5z9kHzpX42I8hWCqYEJQ3TEr1gsx4LRRlTLCXZMYYa2i1bPlr8ialn4zxSop6Rn4dIup8RJ_hasomHDGBHjJGuPYWM5qs-xHh8ts5PLh8CxsXU6Y75xG2fZyy866HeUkXsB-nBDfoMQcz6keYl3zxqRCPaOF8ijq74OHfvPl-1Ab7sChQTIVdB1_0ptJd9E7jpjvIAWr4gTomuETrtIdNGMfwQEvNeci3COvV_rC9WR0u4Hue7NNb8mrQY8J3f-MZud5cHNZf6e7qy3a92lHDVa2oZK1pjOL1UlbGVFJZxTiKlnNeibrt-1ZpPRgpdd3Wy4bZytpaqUoLYRo5DPKM8JOuiSGliEN3F91Rx6eOs-7Zle6PK92zK93JlcJ8PjFYFrt3GLtkHHpTLovl2Z0N7j_0b5A3lbc</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Allan, John N.</creator><creator>Siddiqi, Tanya</creator><creator>Kipps, Thomas J.</creator><creator>Kuss, Bryone J.</creator><creator>Badoux, Xavier C.</creator><creator>Barrientos, Jacqueline C.</creator><creator>Tedeschi, Alessandra</creator><creator>Opat, Stephen</creator><creator>Flinn, Ian W.</creator><creator>Gonzalez Barca, Eva</creator><creator>Jacobs, Ryan</creator><creator>Szafer-Glusman, Edith</creator><creator>Zhou, Cathy</creator><creator>Szoke, Anita</creator><creator>Wierda, William G.</creator><creator>Ghia, Paolo</creator><creator>Tam, Constantine S.</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study</title><author>Allan, John N. ; Siddiqi, Tanya ; Kipps, Thomas J. ; Kuss, Bryone J. ; Badoux, Xavier C. ; Barrientos, Jacqueline C. ; Tedeschi, Alessandra ; Opat, Stephen ; Flinn, Ian W. ; Gonzalez Barca, Eva ; Jacobs, Ryan ; Szafer-Glusman, Edith ; Zhou, Cathy ; Szoke, Anita ; Wierda, William G. ; Ghia, Paolo ; Tam, Constantine S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1858-307c6c815934cc438d801e271114257bb78aafc33a575960d4dd5884a22c63ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Allan, John N.</creatorcontrib><creatorcontrib>Siddiqi, Tanya</creatorcontrib><creatorcontrib>Kipps, Thomas J.</creatorcontrib><creatorcontrib>Kuss, Bryone J.</creatorcontrib><creatorcontrib>Badoux, Xavier C.</creatorcontrib><creatorcontrib>Barrientos, Jacqueline C.</creatorcontrib><creatorcontrib>Tedeschi, Alessandra</creatorcontrib><creatorcontrib>Opat, Stephen</creatorcontrib><creatorcontrib>Flinn, Ian W.</creatorcontrib><creatorcontrib>Gonzalez Barca, Eva</creatorcontrib><creatorcontrib>Jacobs, Ryan</creatorcontrib><creatorcontrib>Szafer-Glusman, Edith</creatorcontrib><creatorcontrib>Zhou, Cathy</creatorcontrib><creatorcontrib>Szoke, Anita</creatorcontrib><creatorcontrib>Wierda, William G.</creatorcontrib><creatorcontrib>Ghia, Paolo</creatorcontrib><creatorcontrib>Tam, Constantine S.</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Allan, John N.</au><au>Siddiqi, Tanya</au><au>Kipps, Thomas J.</au><au>Kuss, Bryone J.</au><au>Badoux, Xavier C.</au><au>Barrientos, Jacqueline C.</au><au>Tedeschi, Alessandra</au><au>Opat, Stephen</au><au>Flinn, Ian W.</au><au>Gonzalez Barca, Eva</au><au>Jacobs, Ryan</au><au>Szafer-Glusman, Edith</au><au>Zhou, Cathy</au><au>Szoke, Anita</au><au>Wierda, William G.</au><au>Ghia, Paolo</au><au>Tam, Constantine S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>224</spage><epage>227</epage><pages>224-227</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-160338</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.224-227 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_160338 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T06%3A01%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20Outcomes%20after%20Undetectable%20MRD%20with%20First-Line%20Ibrutinib%20(Ibr)%20Plus%20Venetoclax%20(Ven):%20Fixed%20Duration%20Treatment%20(Placebo)%20Versus%20Continued%20Ibr%20with%20up%20to%205%20Years%20Median%20Follow-up%20in%20the%20CAPTIVATE%20Study&rft.jtitle=Blood&rft.au=Allan,%20John%20N.&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=224&rft.epage=227&rft.pages=224-227&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-160338&rft_dat=%3Celsevier_cross%3ES0006497122016354%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122016354&rfr_iscdi=true |